Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Vestibular Schwannoma in NF2
NCT01207687Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in vestibular schwannoma (VS), sponsored by National Cancer Institute. Primary endpoint: Proportion of Patients With Hearing Response at 12 months. Started Oct 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT01207687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207687.